CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Helix Biopharma Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Helix Biopharma Corp.
401 Bay Street,, Suite 2704,
PO Box 4
Phone: (905) 841-2300p:905 841-2300 TORONTO, ON  M5H 2Y4  Canada Ticker: HBPHBP
Business Summary
Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
10/31/20237/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director JacekAntas 12/8/2022 4/18/2022
Chief Financial Officer HatemKawar 5/18/2022 5/18/2022
Independent Director Margaret I.Laube 12/8/2022 12/8/2022
Independent Director JerzyLeszczynski 4/18/2022 4/18/2022
Independent Director ChristopherMaciejewski 4/18/2022 4/18/2022

Business Names
Business Name
HBP
Helix Biopharma Corp.
Helix Polska
Helix Polska sp.z o.o
Helix Product Development(Ireland) Limited

General Information
Number of Employees: 9 (As of 7/31/2023)
Outstanding Shares: 216,674,415 (As of 10/31/2023)
Shareholders: 141
Stock Exchange: TSE
Fax Number: (905) 841-2244


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024